Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.

European journal of haematology - 1 Apr 2017

Fathi Amir T, Chen Yi-Bin

Abstract excerpt

FLT3 mutations are present in about one-third of patients with acute myeloid leukemia (AML). Several FLT3 inhibitors have been used in clinical trials, and these include midostaurin, sorafenib, quizartinib, crenolanib, and gilteritinib. Monotherapy with early tyrosine kinase inhibitors (TKIs) did not have much success; however, later generation agents have shown more promising results. Combination with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to FLT3 gene

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 28000291
DOI: 10.1111/ejh.12841

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The role of FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia.PMID 28000291Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging ControversiesSemantic proximity Read ↗

FLT3 Inhibition in Acute Myeloid Leukaemia - Current Knowledge and Future Prospects.Semantic proximity Read ↗

The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibition as a targeted therapy for acute myeloid leukemia.Semantic proximity Read ↗

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.